The growth of Viagra and its impact on the medicinal landscape presents a complex question for investors. While the early sales statistics were impressive, the patent has ended, leading to a wave of copycat alternatives that are eroding earnings. In addition, the market is facing issues related to demographic trends and changing healthcare policies